Retinitis Pigmentosa (RP) Market, By Route of Administration (Topical and Oral), By Diagnosis, By Treatment Type, By Disease Type, By End-Users, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4518
|
Published Date
November 2025
|
Pages
365
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
The Retinitis Pigmentosa (RP) Market size was valued at US$ 14,789.90 Million in 2024, expanding at a CAGR of 7.4% from 2025 to 2032.
Retinitis Pigmentosa (RP) is a group of inherited retinal disorders characterized by progressive vision loss due to damage to the retina, the light-sensitive tissue at the back of the eye. Individuals with RP often experience impaired night vision, gradual loss of peripheral vision, and, in advanced stages, complete blindness. The RP market is primarily driven by improvements in the diagnosis of inherited retinal diseases, greater access to genetic testing, and rapid advancements in gene therapy, stem-cell therapy, and optogenetic approaches that enable more targeted and personalized treatments. Market growth, however, is constrained by the high cost of gene therapies and the limited availability of approved treatments beyond Luxturna. Key trends shaping the market include increased investment in AAV- and CRISPR-based therapeutic platforms and a growing focus on early genetic screening. According to the World Health Organization, over 285 million people worldwide suffer from vision impairment, prompting gove
Retinitis Pigmentosa (RP) Market- Market Dynamics
Rising Healthcare Expenditure Fuels Growth in the Retinitis Pigmentosa Market
The rising healthcare expenditure is expected to drive growth in the retinitis pigmentosa (RP) market. Healthcare spending encompasses costs related to medical treatments, medications, hospitalizations, preventive care, and supportive services, reflecting the overall investment in health within a population. Increasing costs are driven by the adoption of advanced medical technologies, aging populations, and the growing prevalence of chronic diseases. In the RP market, expenditures focus on enhancing diagnostic capabilities, developing effective therapies, and providing supportive care for vision loss management. For instance, according to the U.S. National Institutes of Health, healthcare spending in the United States rose by 4.1% in 2022, reaching $4.5 trillion, compared to a 3.2% increase in 2021. This trend underscores how rising healthcare investment is supporting the expansion of the retinitis pigmentosa market.
Retinitis Pigmentosa (RP) Market- Segmentation Analysis:
The worldwide market is segmented on the basis of Route of Administration, Diagnosis, Treatment Type, Disease Type, End-Users, and Region.
In the treatment type segment, gene therapy is expected to remain a primary growth driver throughout the forecast period. Gene therapy for retinitis pigmentosa (RP) involves delivering functional genes to patient cells to correct disease-causing mutations. Luxturna (voretigene neparvovec-rzyl) is currently the only FDA-approved therapy for biallelic RPE65 mutations, restoring functional gene expression in retinal cells. Beyond Luxturna, several candidates are progressing through clinical trials, utilizing AAV and other vector technologies to address a broader spectrum of mutations. Sustained investment from leading biopharmaceutical companies is fueling development and shaping the segment’s upward trajectory. For example, in May 2025, Beacon Therapeutics Holdings Limited reported six-month interim safety and efficacy results from the Phase 2 DAWN trial of its lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP).
Within the same segment, Vitamin A supplements continue to be an essential and historically significant therapy for RP. Specifically, retinol palmitate has been studied for its potential to slow photoreceptor degeneration in some patients. Given the genetic heterogeneity of RP and the limited availability of broadly approved gene therapies for many subtypes, vitamin A offers a low-cost, accessible intervention that may help delay retinal function decline. It can also serve as a complementary approach alongside advanced therapies. According to the National Eye Institute (NEI), a study conducted between 1984 and 1992 found that a daily intake of 15,000 IU of vitamin A palmitate could slow the progression of functional retinal decline, as measured by electroretinography (ERG), highlighting its continued relevance in RP management.
Retinitis Pigmentosa (RP) Market- Geographical Insights
In 2025, North America emerged as a leading region in the retinitis pigmentosa market, accounting for over 45.2% of global market share. The region’s growth is supported by advanced healthcare infrastructure, substantial R&D investments, and a rising prevalence of retinal diseases. Regulatory support from agencies such as the FDA facilitates the approval of innovative therapies, accelerating market expansion. Increased awareness of genetic disorders and rising demand for effective treatments are further driving growth. The United States serves as the primary contributor, with key players like Regeneron Pharmaceuticals and Spark Therapeutics at the forefront, while Canada plays a supportive role through focused R&D initiatives. Strategic collaborations between biotech companies and academic institutions strengthen the competitive landscape, expanding the pipeline of novel therapies. Additionally, the presence of major pharmaceutical firms ensures a robust market environment that fosters innovation, accessibil
United States Retinitis Pigmentosa (RP) Market- Country Insights
North America, particularly the United States and Canada, is home to a large concentration of leading pharmaceutical and biotechnology companies actively engaged in developing novel therapies for improved treatment outcomes. For example, in August 2024, Ocugen, Inc., a biotechnology firm specializing in gene and cell therapies, announced that Health Canada had issued a No Objection Letter to initiate the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy candidate for retinitis pigmentosa (RP). Such initiatives, focused on the development of innovative therapeutics, are expected to further drive regional market growth.
Retinitis Pigmentosa (RP) Market- Competitive Landscape:
The Retinitis Pigmentosa (RP) market is highly competitive, with a broad ecosystem of stakeholders, including pharmaceutical companies, biotechnology firms, academic institutions, research organizations, and healthcare providers. These entities are actively involved in research and development of novel therapies, commercialization of existing treatments, and patient care services. Government agencies also play a critical role in advancing RP research; for example, the National Institutes of Health (NIH) in the United States and the European Commission’s Horizon 2020 program provide funding and support for research initiatives, fostering innovation, collaboration, and therapeutic advancements in ophthalmology.
Recent Developments:
- In December 2024, Bausch + Lomb (a subsidiary of Bausch Health) acquired Elios Vision Inc., developer of the ELIOS system, a minimally invasive glaucoma surgery (MIGS) procedure utilizing an excimer laser. This acquisition highlights Bausch + Lomb’s commitment to advanced ocular therapies and improving patient care globally.
- In May 2024, Johnson & Johnson launched the EYE-RD Global Registry at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). This first-of-its-kind non-interventional registry collects longitudinal clinical data on patients with inherited retinal diseases (IRDs), such as X-linked RP, providing real-world insights into disease progression and patient experiences to support research, diagnosis, and treatment strategies.
- In August 2025, Novartis (CH) announced a strategic collaboration with a leading biotechnology company to co-develop a novel gene therapy for RP. This partnership leverages both organizations’ expertise in genetics to potentially accelerate development timelines and expand therapeutic options, reflecting an industry-wide trend toward collaborative innovation.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Bausch Health Companies Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- AGTC
- MeiraGTx Limited
- ReNeuron Group plc
- ProQR Therapeutics
- Sun Pharmaceutical Industries Ltd.
- Allergan
- Astellas Pharma Inc.
- AstraZeneca
- Caladrius Biosciences, Inc.
- Genethon
- Gensight Biologics
- Johnson & Johnson Private Limited
- Orphagen Pharmaceuticals, Inc
- Clino Corporation
- Spark Therapeutics, Inc
- Grupo Ferrer International, S.A.
- Nanovector S.r.l
- Mimetogen Pharmaceuticals Inc.
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Topical
- Oral
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2019 - 2032
- Electroretinogram
- Genetic Testing
- Visual Field Testing
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032
- Retinal Implants
- Vitamin A Supplements
- Calcium channel blockers
- Docosahexaenoic acid (DHA)
- Gene Therapy
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032
- Autosomal Dominant
- X-linked RP
- Autosomal Recessive
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Homecare
- Specialty Clinics
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Retinitis Pigmentosa (RP) Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Retinitis Pigmentosa (RP) Market Snippet by Route of Administration
2.1.2. Retinitis Pigmentosa (RP) Market Snippet by Diagnosis
2.1.3. Retinitis Pigmentosa (RP) Market Snippet by Treatment Type
2.1.4. Retinitis Pigmentosa (RP) Market Snippet by Disease Type
2.1.5. Retinitis Pigmentosa (RP) Market Snippet by End-Users
2.1.6. Retinitis Pigmentosa (RP) Market Snippet by Country
2.1.7. Retinitis Pigmentosa (RP) Market Snippet by Region
2.2. Competitive Insights
3. Retinitis Pigmentosa (RP) Key Market Trends
3.1. Retinitis Pigmentosa (RP) Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Retinitis Pigmentosa (RP) Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Retinitis Pigmentosa (RP) Market Opportunities
3.4. Retinitis Pigmentosa (RP) Market Future Trends
4. Retinitis Pigmentosa (RP) Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Retinitis Pigmentosa (RP) Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Retinitis Pigmentosa (RP) Market Landscape
6.1. Retinitis Pigmentosa (RP) Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Retinitis Pigmentosa (RP) Market – By Route of Administration
7.1. Overview
7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
7.1.2. Topical
7.1.3. Oral
7.1.4. Others
8. Retinitis Pigmentosa (RP) Market – By Diagnosis
8.1. Overview
8.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
8.1.2. Electroretinogram
8.1.3. Genetic Testing
8.1.4. Visual Field Testing
8.1.5. Others
9. Retinitis Pigmentosa (RP) Market – By Treatment Type
9.1. Overview
9.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
9.1.2. Retinal Implants
9.1.3. Vitamin A Supplements
9.1.4. Calcium channel blockers
9.1.5. Docosahexaenoic acid (DHA)
9.1.6. Gene Therapy
9.1.7. Others
10. Retinitis Pigmentosa (RP) Market – By Disease Type
10.1. Overview
10.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
10.1.2. Autosomal Dominant
10.1.3. X-linked RP
10.1.4. Autosomal Recessive
11. Retinitis Pigmentosa (RP) Market – By End-Users
11.1. Overview
11.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
11.1.2. Hospitals
11.1.3. Homecare
11.1.4. Specialty Clinics
11.1.5. Others
12. Retinitis Pigmentosa (RP) Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Retinitis Pigmentosa (RP) Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Retinitis Pigmentosa (RP) Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Retinitis Pigmentosa (RP) Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Retinitis Pigmentosa (RP) Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Retinitis Pigmentosa (RP) Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Retinitis Pigmentosa (RP) Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Bausch Health Companies Inc.
13.2.2. Novartis AG
13.2.3. Ionis Pharmaceuticals, Inc.
13.2.4. AGTC
13.2.5. MeiraGTx Limited
13.2.6. ReNeuron Group plc
13.2.7. ProQR Therapeutics
13.2.8. Sun Pharmaceutical Industries Ltd.
13.2.9. Allergan
13.2.10. Astellas Pharma Inc.
13.2.11. AstraZeneca
13.2.12. Caladrius Biosciences, Inc.
13.2.13. Genethon
13.2.14. Gensight Biologics
13.2.15. Johnson & Johnson Private Limited
13.2.16. Orphagen Pharmaceuticals, Inc
13.2.17. Clino Corporation
13.2.18. Spark Therapeutics, Inc
13.2.19. Grupo Ferrer International, S.A.
13.2.20. Nanovector S.r.l
13.2.21. Mimetogen Pharmaceuticals Inc.
13.2.22. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Bausch Health Companies Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- AGTC
- MeiraGTx Limited
- ReNeuron Group plc
- ProQR Therapeutics
- Sun Pharmaceutical Industries Ltd.
- Allergan
- Astellas Pharma Inc.
- AstraZeneca
- Caladrius Biosciences, Inc.
- Genethon
- Gensight Biologics
- Johnson & Johnson Private Limited
- Orphagen Pharmaceuticals, Inc
- Clino Corporation
- Spark Therapeutics, Inc
- Grupo Ferrer International, S.A.
- Nanovector S.r.l
- Mimetogen Pharmaceuticals Inc.
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Topical
- Oral
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2019 - 2032
- Electroretinogram
- Genetic Testing
- Visual Field Testing
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032
- Retinal Implants
- Vitamin A Supplements
- Calcium channel blockers
- Docosahexaenoic acid (DHA)
- Gene Therapy
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032
- Autosomal Dominant
- X-linked RP
- Autosomal Recessive
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Homecare
- Specialty Clinics
- Others
GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
